首页 | 本学科首页   官方微博 | 高级检索  
     

胸腺上皮肿瘤中程序性死亡蛋白1及其配体的临床研究进展
引用本文:王凯瑞1,郭 丽1,梁永峰1,李 涛2. 胸腺上皮肿瘤中程序性死亡蛋白1及其配体的临床研究进展[J]. 现代肿瘤医学, 2020, 0(9): 1580-1582. DOI: 10.3969/j.issn.1672-4992.2020.09.036
作者姓名:王凯瑞1  郭 丽1  梁永峰1  李 涛2
作者单位:1.宁夏医科大学研究生院,宁夏 银川 750004;2.宁夏医科大学总医院肿瘤医院肿瘤外科,宁夏 银川 750004
基金项目:National Natural Science Foundation of China(No.81660500);国家自然科学基金(编号:81660500);宁夏医科大学国内一流建设学科临床医学项目资助(编号:NXYLXK2017A05)
摘    要:近年来,随着免疫治疗及肿瘤微环境概念的广泛普及,许多肿瘤靶向位点被人们关注并投以大量的实验研究。程序性死亡蛋白1及其配体(PD-1/PD-L1)作为目前最热门的一个免疫靶点通路,其抑制剂已经应用于多种恶性肿瘤的治疗当中。胸腺上皮肿瘤(TETs)是一种较为少见的肿瘤,目前已有证据表明PD-L1在TETs中存在高表达水平并且其与疾病的预后相关,因此本文针对PD-1/PD-L1在TETs中的临床研究进展作一综述。

关 键 词:胸腺上皮肿瘤  程序性死亡蛋白1  程序性死亡蛋白1配体  免疫治疗

Research progression of PD-1/PD-L1 in thymic epithelial tumors
Wang Kairui1,Guo Li1,Liang Yongfeng1,Li Tao2. Research progression of PD-1/PD-L1 in thymic epithelial tumors[J]. Journal of Modern Oncology, 2020, 0(9): 1580-1582. DOI: 10.3969/j.issn.1672-4992.2020.09.036
Authors:Wang Kairui1  Guo Li1  Liang Yongfeng1  Li Tao2
Affiliation:1.Graduate School of Ningxia Medical University,Ningxia Yinchuan 750004,China;2.Department of Surgical Oncology,Tumor Hospital,General Hospital of Ningxia Medical University,Ningxia Yinchuan 750004,China.
Abstract:Recently,with the widespread popularity of immunotherapy and the concept of tumor microenvironment,many tumor targeting sites have attracted attention and a large number of experimental studies have been conducted.As one of the most popular tumor immune signaling pathway,inhibitor of PD-1/PD-L1 has been used in the treatment of a variety of malignant tumors.TETs is a relatively rare tumor.Currently,there are evidences that PD-L1 has a high expression level in TETs and is related to the prognosis of the disease.Therefore,the aim of this paper is to summarize the research progression of PD-1/PD-L1 in TETs.
Keywords:thymic epithelial tumors   programmed cell death protein 1   programmed cell death ligand 1   immunotherapy
点击此处可从《现代肿瘤医学》浏览原始摘要信息
点击此处可从《现代肿瘤医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号